813445-20-4

Upstream product

• 813445-19-1 ethyl (8R,9S)-8-[[(1R)-1-phenylethyl]amino]-1,4-dioxaspiro[4.5]decane-9-carboxylate 
• 14160-65-7 ethyl 8-oxo-1,4-dioxaspiro[4.5]decane-7-carboxylate 
• 813445-18-0 ethyl (R)-8-((1-phenylethyl)amino)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate 
• 4746-97-8 cyclohexanedione monoethylene ketal 

Downstream Products

• 813445-21-5 [(7R,8R)-8-((R)-1-phenyl-ethylamino)-1,4-dioxa-spiro[4.5]dec-7-yl]-methanol 
• 813445-23-7 ((7R,8R)-7-Hydroxymethyl-1,4-dioxa-spiro[4.5]dec-8-yl)-carbamic acid benzyl ester 
• 1360464-23-8 C₂₃H₂₇NO₄S 
• 1360464-24-9 C₂₃H₂₇NO₆S 
• 1360464-28-3 C₂₁H₂₃NO₅S 
• 1360464-25-0 C₂₁H₂₆N₂O₄S 
• 1360464-27-2 C₂₁H₂₆N₂O₄S 
• 1360464-26-1 C₂₁H₂₆N₂O₄S 
• 852661-49-5 1-((1R,2S,4R)-2-(((3-(4-fluorophenyl)propyl)(propyl)amino)methyl)-4-pivalamidocyclohexyl)-3-(5-ethyl-1,3,4-thiadiazol-2-yl)urea 
• 852661-48-4 1-((1R,2S,4R)-2-(((3-(4-fluorophenyl)propyl)(propyl)amino)methyl)-4-pivalamidocyclohexyl)-3-(5-methyl-1,3,4-thiadiazol-2-yl)urea 
• 852661-26-8 N-{(1R,3S,4R)-3-{[[3-(4-fluorophenyl)propyl](methyl)amino]methyl}-4-[({[3-(1-methyl-1H-tetrazol-5-yl)phenyl]amino}carbonyl)amino]cyclohexyl}-N-methylacetamide 
• 852661-27-9 N-{(1S,3S,4R)-3-{[[3-(4-fluorophenyl)propyl](methyl)amino]methyl}-4-[({[3-(1-methyl-1H-tetrazol-5-yl)phenyl]amino}carbonyl)amino]cyclohexyl}-N-methylacetamide 
• 852661-21-3 N-((1R,3S,4R)-4-({[(5-acetyl-4-methyl-1,3-thiazol-2-yl)amino]carbonyl}amino)-3-{[[3-(4-fluorophenyl)propyl](methyl)amino]methyl}cyclohexyl)-N-methylacetamide 
• 852661-22-4 N-((1S,3S,4R)-4-({[(5-acetyl-4-methyl-1,3-thiazol-2-yl)amino]carbonyl}amino)-3-{[[3-(4-fluorophenyl)propyl](methyl)amino]methyl}cyclohexyl)-N-methylacetamide 

Relevant academic research and scientific papers

Synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamide-derived antagonists of CC chemokine receptor 2 (CCR2)

We report the synthesis of 3-phenylsulfonylmethyl cyclohexylaminobenzamides (4) as CCR2 inhibitors for the potential treatment of inflammatory diseases. Several of the compounds display nanomolar binding affinity for CCR2. The in vitro structure-activity

N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes modulators of chemokine receptors of formula (I), or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.

Process of preparing N-ureidoalkyl-piperidines

The present application describes a process of preparing a compound of formula (IV), or salt or stereoisomer thereof: wherein Pg, at each occurrence, is independently selected from an amine protecting group; comprising the steps of reacting a compound of Formula with a reducing agent to give a compound of Formula III: reacting the compound of formula (III) with an amine of formula (IIa) using reductive amination to give the compound of formula (III)

N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

The present application describes modulators of chemokine receptor activity of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases, as well as autoimmune pathologies such as rheum